AzTrials
AzTrials

Peripheral Artery DiseaseMAvERICNCT06114732

Motivating Physical Activity With Behavioural interVention and Electrical Stimulation Remotely in Intermittent Claudication

A study testing Walking exercise behaviour change intervention + TENS in people with Peripheral Artery Disease and Intermittent Claudication, run by Glasgow Caledonian University at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Peripheral Arterial Disease (PAD) is a common vascular disease which commonly causes limb pain and reduced exercise tolerance termed Intermittent Claudication (IC). People with PAD and IC have impaired quality of life, reduced walking ability, and increased mortality compared to those who do not have the condition. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Walking exercise behaviour change intervention + TENS
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteUnited Kingdom
Study dates
29 Jan 2024to 1 Dec 2026
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of symptomatic Peripheral Arterial Disease (PAD) including resting ABPI <0.9 in at least one leg
  • Stable IC for ≥3 months
  • Walking limited primarily by claudication
  • Able to read and speak English to a level allowing satisfactory completion of the study procedures
  • Able to provide written informed consent for participation

Who cannot join

  • Planned surgical or endovascular intervention for PAD within the next 3 months
  • Critical limb ischaemia
  • The presence of any absolute contraindications to exercise testing/training as defined by the American College of Sports Medicine (ACSM)
  • Previous experience of using TENS for PAD
  • Contraindications to TENS (including epilepsy, dermatological conditions, indwelling electrical pumps/pacemakers) and inability to apply TENS independently.
  • Patients who require walking aids including artificial limbs
Show all 10Show fewer
  • Major surgery, myocardial infarction or stroke/ TIA in the previous 6 months
  • Co-morbidities that cause pain or limit walking to a greater extent than IC (e.g. severe arthritis, respiratory conditions)
  • Severe peripheral neuropathies above the ankle.
  • Participation in another research protocol

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sean Paul Carroll, PhDCandidate contact

+44 (0)141 331 8306

sean.carroll@gcu.ac.uk

United Kingdom1 site, 1 recruiting
  • NHS Lanarkshire

    Glasgow, Lanarkshire, G75 8RG

    Sean Paul Carroll, 0141 331 8306, sean.carroll@gcu.ac.uk

    Chris Seenan, 0141 331 8151, chris.seenan@gcu.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Motivating Physical Activity With Behavioural interVention and Electrical Stimulation Remotely in People With Intermittent Claudication (MAvERIC): a Feasibility Randomised Controlled Trial

Peripheral Arterial Disease (PAD) is a common vascular disease which commonly causes limb pain and reduced exercise tolerance termed Intermittent Claudication (IC). People with PAD and IC have impaired quality of life, reduced walking ability, and increased mortality compared to those who do not have the condition.

Improving physical activity (PA) is important in individuals with IC it can improve function, morbidity and mortality rates. While supervised exercise classes are recommended by healthcare authorities they are geographically sparse, and not always accessible due to individuals walking limitations. While home-based exercise can be accessible and improve walking ability, it can be challenging for people with IC to initially plan, conduct, and stay motivated to complete a walking program unsupported, especially when they experience limb pain when walking.

Read more

Investigators have shown that Transcutaneous Electrical Nerve Stimulation (TENS), a non-invasive pain management device, with aims to improve pain and walking distances in patients with IC may be an acceptable modality alongside advice and support from a physiotherapist to overcome these challenges. Investigators have also shown that motivational interviewing, education, and goal-setting with a physiotherapist (physical therapist) has the potential to increase PA, and quality of life.

This study aims to conduct a feasibility trial of four telehealth physiotherapy sessions, alongside the provision of a CE-marked TENS device to reduce limb pain during physical activity. This will be compared to the usual care offered in NHS Lanarkshire

Read the detailed description

Peripheral Arterial Disease (PAD) is a common vascular disease which is symptomatic in 2.4% of 50 to 89 year olds in the UK population. Symptomatic PAD initially presents clinically as limb pain and reduced exercise intolerance termed Intermittent Claudication (IC). Patients with PAD and IC have impaired quality of life due to reduced physical capacity and 3-4 times increased mortality compared to age and sex matched controls.

Improving daily physical activity (PA) is particularly important in individuals with IC as lower PA levels have been recognised as a strong predictor of increased morbidity and mortality in this population. Supervised exercise programs are recommended in clinical guidelines with proven efficacy to help increase physical activity, improve quality of life and contribute to secondary prevention of adverse cardiovascular events (ACVE). Despite this, provision of classes is varied geographically in the UK, and generally is centralised away from rural areas, which may limit uptake and adherence. An alternative to this exercise format may be home-based exercise in the format of a walking-based behaviour change intervention. Home-based exercise for people with intermittent claudication demonstrate a low number of related adverse events, and in the case of walking-based programmes, are likely more accessible, require little equipment, and involve increasing an activity of daily living (ADL) in people with intermittent claudication. Therefore, there is a need for investigation to the acceptability of novel methods of increasing physical activity in a home-based setting.

Lack of self-efficacy, attributed to poor understanding of the disease and uncertainty regarding the importance of exercise, has been shown to be a major barrier to exercise uptake in patients with PAD and IC. Moreover, home based exercise for the self-management of IC is less established in the literature than SEP and there are concerns of low adherence without clinician monitoring. However, if an engaging intervention feasible to the patient and healthcare provider can be established there is potential for greater equality in care, reduced healthcare utilisation and improvement of self-management of PAD in the population.

A proposed intervention to augment walking based physical activity is Transcutaneous electrical nerve stimulation (TENS). TENS a low-cost, non-invasive pain management device with aims to improve pain and walking distances in patients with IC. In our exploratory study we demonstrated that TENS applied to the lower limb during treadmill walking significantly improved pain and increased treadmill walking distances above placebo levels. In addition, Motivating Structured Walking Activity in People with Intermittent Claudication (MOSAIC) is a walking based behavioural intervention utilising motivational interviewing to help people with PAD and IC increase their physical activity. This may help patients plan and overcome barriers to increasing their physical activity by joint clinician and patient set physical activity goals. Both TENS and MOSAIC have potential for remote delivery which could have effects on secondary prevention of ACVE alongside improved function and quality of life for this high-risk group, and ensuring that patients can continue to undertake exercise where it is not feasible to attend SEP, or where fluctuations in social-distancing restrictions occur.

Although TENS and behavioural interventions have been utilised previously in this population to improve physical activity. Neither MOSAIC or TENS have been utilised with aim to improve free living physical activity measured using an accelerometer, and there is a lack of data investigating these outcomes with home based exercise in general. While the author is aware of ongoing works investigating these outcomes, no trial to date has been developed a priori to evaluate the delivery of these treatments remotely in this population.

The primary aim of MAvERIC is to determine the acceptability and feasibility of electrical stimulation via a low-cost CE-marked device, and a remotely delivered walking based behavioural intervention (MOSAIC) in patients with PAD, compared to usual care.

The following research questions will be answered by this project:

  1. What is the feasibility (i.e. recruitment and retention rates, adherence, safety, sample size for a definitive trial, potential for effectiveness) of conducting a definitive RCT utilising TENS or MOSAIC as an intervention compared to usual care?
  2. How acceptable is TENS and MOSAIC interventions to patients with IC?
  3. What are the effects of TENS and MOSAIC as interventions on free living physical activity, pain related, and quality of life PROMs?
Being tested
Walking exercise behaviour change intervention + TENS
Keywords
Transcutaneous electrical nerve stimulation, Electrical Stimulation, Pain Management, Physiotherapy, Education, Motivational Interviewing, Feasibility
Medical subject headings
Peripheral Arterial Disease, Intermittent Claudication, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Walking exercise behaviour change intervention + TENSBehavioural

    MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.

    HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake.

Study groups in NCT06114732
Study groupRoleWhat they receive
Walking exercise behaviour change intervention + TENSExperimentalParticipants in the Intervention groups will be asked to attend four telehealth appointments with a physiotherapist. They will also be provided with a TENS machine and training at the baseline appointment on how to use it. They will be instructed to use it daily as their symptoms require for 12 weeks. The device will be set at High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
Receives: Behavioral: Walking exercise behaviour change intervention + TENS
Usual Care controlNo interventionUsual Care at NHS Lanarkshire Vascular Services and/or Intermittent Claudication service.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment rates

    Measure recruitment rates (ratio of patients who consent to participate to potentially eligible patient recorded via the study screening log

    Measured: End of Study (12 weeks)

  2. Participant retention rate

    Ratio of patients who completed the intervention and outcome assessment to the patient who consented

    Measured: End of Study (12 weeks)

  3. Adverse events

    Record defined adverse events in all groups

    Measured: End of Study (12 weeks)

  4. Uptake of interventions

    Measure uptake of intervention via log of TENS use and attendance at physiotherapy appointments and follow up phone calls

    Measured: End of Study (12 weeks)

  5. Qualitative analysis of participant experience of trial

    Analysis of semi-structured discussions with participants regarding experience of trial and interventions

    Measured: End of Study (12 weeks)

  6. Theoretical framework of acceptability (TFA) questionnaire

    Quantitative measurement of Acceptability of Intervention compared with usual care

    Measured: End of Study (12 weeks)

Secondary outcomes (11)
  1. Change in daily physical activity

    Total number of steps (activpal step counts)

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  2. Change in daily physical activity

    Upright and sitting events

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  3. Change in daily physical activity

    Walking events

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  4. Change in daily physical activity

    Event-based claudication index (ratio of walking events to upright events) participants undertake in a day

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  5. Change in daily physical activity

    Total duration of walking activity in minutes and seconds

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  6. Patient Reported Outcome Measure

    Disease specific quality of life will be as assessed using the Intermittent Claudication Questionnaire (ICQ).

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  7. Patient Reported Outcome Measures

    Generic quality of life via the EQ-5D-3L

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  8. Patient Reported Outcome Measures

    Pain quality will be recorded using the Short Form McGill Pain Questionnaire (MPQ)

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  9. Patient Reported Outcome Measures

    Average Pain intensity in the past 7 days will be recorded using a Visual Analogue Scale

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  10. Patient Reported Outcome Measures

    Pain self-efficacy via. the Pain Self-Efficacy (PSEQ)

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

  11. Patient Reported Outcome Measures

    Pain Catastrophizing via. the Pain Catastrophizing Scale (PCS)

    Measured: Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2023
  2. Study start29 Jan 2024
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06114732
Sponsor's protocol ID
332468
Other IDs
HLS/PSWAHS/22/224
Acronym
MAvERIC
Status last verified
Aug 2025
First submitted
30 Oct 2023
Last updated
2 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in